高级检索
当前位置: 首页 > 详情页

Changes of immune cells in patients with hepatocellular carcinoma treated by radiofrequency ablation and hepatectomy, a pilot study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]First Peoples Hosp Fuyang Hangzhou, Dept Hepatobiliary Surg, Hangzhou 311400, Peoples R China [2]Sun Yat Sen Univ, Affiliated Hosp 8, Dept Neurol, Shennanzhong Rd 3025, Shenzhen 518033, Guangdong, Peoples R China [3]Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 4313192, Japan [4]Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndrome, Fuzhou 350122, Peoples R China [5]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Gastrointestinal Surg, Hangzhou 310003, Peoples R China
出处:
ISSN:

关键词: small HCC RFA hepatectomy immune cells PBMCs

摘要:
In this pilot study, we compared the dynamic changes of circulating immune cells between patients with hepatocellular carcinoma (HCC) who underwent radio frequency ablation (RFA) and hepatectomy. Seventy-three patients were enrolled in this study. Flow cytometry assay was performed to determine the immune cells in the peripheral blood mononuclear cells (PBMCs) before treatment and on days 7, 14, and 28 after treatment. We found that in the RFA group, the circulating cluster of differentiation (CD)4+ cells, the CD4+/CD8+ ratio, and natural killer (NK) cells continued to increase, and the circulating CD8+ cells continued to decrease after the treatment. In contrast, in the surgery group, the circulating CD4+ cells and CD4+/ CD8+ ratio decreased over the first seven postoperative days and then began to increase, and CD8+ cells decreased on the first 7 postoperative days and began to increase thereafter. The changes of immune cells in tumor tissues consisted of an increase in the number of CD4+ cells, CD8+ cells, CD3+ cells, and NK cells immediately after RFA. Our results show that postoperative immune function continued to improve after RFA, but after surgery, it decreased in the first week and started to improve thereafter. These findings are important for clinicians when selecting the appropriate therapy for HCC.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 生物
小类 | 4 区 生物学
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 生物学
JCR分区:
出版当年[2019]版:
Q4 BIOLOGY
最新[2023]版:
Q3 BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]First Peoples Hosp Fuyang Hangzhou, Dept Hepatobiliary Surg, Hangzhou 311400, Peoples R China
通讯作者:
通讯机构: [2]Sun Yat Sen Univ, Affiliated Hosp 8, Dept Neurol, Shennanzhong Rd 3025, Shenzhen 518033, Guangdong, Peoples R China [3]Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 4313192, Japan [4]Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndrome, Fuzhou 350122, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号